Optimizing the pharmacology of statins: characteristics of rosuvastatin

This publication has 12 references indexed in Scilit:

• Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia
  Published by Elsevier ,2002
• Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
  The American Journal of Cardiology, 2001
• A new HMG‐CoA reductase inhibitor, rosuvastatin, exerts anti‐inflammatory effects on the microvascular endothelium: the role of mevalonic acid
  British Journal of Pharmacology, 2001
• Rosuvastatin (20, 40 and 80 MG) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 MG) in patients with heterozygous familial hypercholesterolaemia
  Atherosclerosis Supplements, 2001
• Structural Mechanism for Statin Inhibition of HMG-CoA Reductase
  Science, 2001
• Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.
  The American Journal of Cardiology, 2001
• Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells
  Atherosclerosis, 2000
• Pharmacological properties of ZD4522 — A new HMG-CoA reductase inhibitor
  Atherosclerosis, 2000
• Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522
  Atherosclerosis, 2000
• Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat
  Atherosclerosis, 2000